Recent Press Releases

Patients Continuing On Sanofi's Lantus® Had Lower Blood Sugar Levels Than Those who Switched to Insulin Detemir

Patients Continuing On Sanofi's Lantus® Had Lower Blood Sugar Levels Than Those who Switched to Insulin Detemir Real World Outcome Study of Patients with Type 2 Diabetes Presented at American...

New phase 3 study shows efficacy and safety of Victoza® (liraglutide [rDNA origin] injection) for the treatment of type 2 diabetes in adults with moderate renal impairment

New phase 3 study shows efficacy and safety of Victoza® (liraglutide [rDNA origin] injection) for the treatment of type 2 diabetes in adults with moderate renal impairment San Francisco, U.S., 14...

New one-year data of IDegLira shows glucose-lowering effect was maintained for people with type 2 diabetes

New one-year data of IDegLira shows glucose-lowering effect was maintained for people with type 2 diabetes San Francisco, U.S., 14 June 2014 – New Phase 3a findings show IDegLira, the...

Sanofi and Medtronic to Form Strategic Alliance in Diabetes to Improve Patient Experience and Outcomes

Sanofi and Medtronic to Form Strategic Alliance in Diabetes to Improve Patient Experience and Outcomes Paris and Minneapolis, Minn. - June 14, 2014 - Sanofi (EURONEXT: SAN and NYSE: SNY) and...

GSK presents new data for once-weekly Tanzeum/Eperzan (albiglutide) showing blood glucose lowering up to three years in type 2 diabetes

GSK presents new data for once-weekly Tanzeum/Eperzan (albiglutide) showing blood glucose lowering up to three years in type 2 diabetes New data from secondary analyses of four randomised phase III...

Novartis Holly Springs facility becomes first US pandemic-ready site licensed by the FDA to produce cell-culture influenza vaccines

Novartis Holly Springs facility becomes first US pandemic-ready site licensed by the FDA to produce cell-culture influenza vaccines Cell-culture technology is a modern alternative to manufacture...

Type 2 Diabetes: Investigational Empagliflozin/Linagliptin Combination Tablet Showed Reduction in Blood Glucose in Two Phase III Trials

- For those taking metformin, empagliflozin/linagliptin combination tablet showed statistically significant reductions in blood glucose vs.

Studies Show Investigational New Insulin Glargine Product from Lilly and Boehringer Ingelheim Similar Safety and Efficacy Profile to Lantus®

Companies present comprehensive data for LY2963016, investigational new insulin glargine product

SAN FRANCISCO,

Lilly's Once-Weekly Dulaglutide Shows Similar Reductions in Average Blood Glucose Levels as Once-Daily Liraglutide in Head-to-Head Trial

Once-Weekly Dulaglutide 1.5 mg Also Demonstrates Weight Loss, Low Rates of Hypoglycemia in AWARD-6 Trial

SAN FRANCISCO,

Lilly's Basal Insulin Peglispro Shows Novel Mechanism of Action

Data presented at the 74th American Diabetes Association Scientific Sessions® expand body of evidence for the mechanism of action of basal insulin peglispro in healthy human subjects

Abbott Declares 362nd Consecutive Quarterly Dividend

ABBOTT PARK, Ill., June 13, 2014 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend

GSK announces results of Phase III PETIT2 study of eltrombopag (Promacta™/Revolade™) in paediatric patients with chronic immune thrombocytopenia

GSK announces results of Phase III PETIT2 study of eltrombopag (Promacta™/Revolade™) in paediatric patients with chronic immune thrombocytopenia GlaxoSmithKline (GSK) plc today announced...

Teva Announces U.S. Court of Appeals Upholds Ruling Confirming Invalidity of Baraclude® Patent

Teva Announces U.S. Court of Appeals Upholds Ruling Confirming Invalidity of Baraclude® Patent JERUSALEM--(BUSINESS WIRE)--Jun. 12, 2014-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)...

Eli Lilly and Company (LLY) Taps Prominent Healthcare Official For Vice President Job

Eli Lilly and Company (LLY) Taps Prominent Healthcare Official For Vice President Job Dr. Ora Pescovitz, the former CEO of Riley Hospital for Children, is returning to Indianapolis to work for Eli...

VIVUS Files Lawsuit Against Actavis for Infringement of Qsymia Patents

MOUNTAIN VIEW, CA, Jun 12, 2014 (Marketwired via COMTEX) -- VIVUS, Inc. VVUS +0.57% today announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against...

Foamix Establishes U.S. Subsidiary And Strengthens Executive Management With Appointment Of Senior U.S. Leadership Team

Foamix Establishes U.S. Subsidiary And Strengthens Executive Management With Appointment Of Senior U.S. Leadership Team REHOVOT, Israel and BRIDGEWATER, N.J. , June 11, 2014 (GLOBE NEWSWIRE) --...

Aerie Pharmaceuticals, Inc. (AERI) Elects James Mazzo To The Company's Board Of Directors

Aerie Pharmaceuticals, Inc. (AERI) Elects James Mazzo To The Company's Board Of Directors Aerie Pharmaceuticals, Inc. (Nasdaq:AERI) today announced that James Mazzo has been elected to the Company's...

Shire Agrees to FDA Request to Conduct Clinical Trials Investigating the Potential Use of Vyvanse(R) (lisdexamfetamine dimesylate) in Preschool-Age Children with ADHD

Shire Agrees to FDA Request to Conduct Clinical Trials Investigating the Potential Use of Vyvanse(R) (lisdexamfetamine dimesylate) in Preschool-Age Children with ADHD LEXINGTON, Massachusetts, Jun...

New long-term data on Cimzia® (certolizumab pegol) presented at EULAR 2014 shows sustained outcomes in patients with spondyloarthritis

New long-term data on Cimzia® (certolizumab pegol) presented at EULAR 2014 shows sustained outcomes in patients with spondyloarthritis New 96-week interim data cut from the RAPIDTM-PsA and -axSpA...

Lilly Announces Top-Line Results Of Phase III Hepatocellular Carcinoma Trial

INDIANAPOLIS, June 11, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the P